CN106604931B - 靶向表面活性蛋白a受体的组合物和方法 - Google Patents

靶向表面活性蛋白a受体的组合物和方法 Download PDF

Info

Publication number
CN106604931B
CN106604931B CN201580042405.4A CN201580042405A CN106604931B CN 106604931 B CN106604931 B CN 106604931B CN 201580042405 A CN201580042405 A CN 201580042405A CN 106604931 B CN106604931 B CN 106604931B
Authority
CN
China
Prior art keywords
sequence
cells
monoclonal antibody
seq
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580042405.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN106604931A (zh
Inventor
兹西斯·克罗尼奥斯
尼尔·克里斯滕森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Penn State Research Foundation
Original Assignee
Penn State Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Penn State Research Foundation filed Critical Penn State Research Foundation
Publication of CN106604931A publication Critical patent/CN106604931A/zh
Application granted granted Critical
Publication of CN106604931B publication Critical patent/CN106604931B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201580042405.4A 2014-07-14 2015-07-14 靶向表面活性蛋白a受体的组合物和方法 Active CN106604931B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462024314P 2014-07-14 2014-07-14
US62/024,314 2014-07-14
US201562121830P 2015-02-27 2015-02-27
US62/121,830 2015-02-27
PCT/US2015/040304 WO2016010978A1 (en) 2014-07-14 2015-07-14 Compositions and methods for targeting of the surfactant protein a receptor

Publications (2)

Publication Number Publication Date
CN106604931A CN106604931A (zh) 2017-04-26
CN106604931B true CN106604931B (zh) 2020-04-21

Family

ID=55078969

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580042405.4A Active CN106604931B (zh) 2014-07-14 2015-07-14 靶向表面活性蛋白a受体的组合物和方法

Country Status (8)

Country Link
US (1) US10077309B2 (https=)
EP (2) EP3733700A1 (https=)
JP (1) JP6495434B2 (https=)
CN (1) CN106604931B (https=)
AU (2) AU2015289831B2 (https=)
CA (2) CA3225495A1 (https=)
ES (1) ES2869909T3 (https=)
WO (1) WO2016010978A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112442126B (zh) * 2019-09-04 2022-07-29 杭州济元基因科技有限公司 一种抗人cs1抗原的单克隆抗体及其car-t细胞
EP4000597A1 (en) * 2020-11-17 2022-05-25 The Boots Company plc Tetrapeptide and compositions comprising tetrapeptides
CN116217718B (zh) * 2022-11-21 2023-08-25 浙江洪晟生物科技股份有限公司 一种猪丹毒抗体检测试剂盒及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1069124A (zh) * 1991-04-26 1993-02-17 活跃表面有限公司 新的抗体及其使用方法
CN102164613A (zh) * 2008-07-25 2011-08-24 生物医学研究所 中和抗甲型流感病毒抗体及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1649038B1 (en) 2003-06-26 2014-07-02 Litron Laboratories Ltd. Method for the enumeration of micronucleated erythrocyte populations while distinguishing platelets and/or platelet-associated aggregates
US8691730B2 (en) * 2007-09-14 2014-04-08 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US8748113B2 (en) 2007-11-15 2014-06-10 The Johns Hopkins University Methods for detecting and monitoring circulating cancer stem cells
US9778264B2 (en) 2010-09-03 2017-10-03 Abbvie Stemcentrx Llc Identification and enrichment of cell subpopulations
CN104936977B (zh) 2012-10-24 2019-10-08 开普敦大学 微管修饰化合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1069124A (zh) * 1991-04-26 1993-02-17 活跃表面有限公司 新的抗体及其使用方法
CN102164613A (zh) * 2008-07-25 2011-08-24 生物医学研究所 中和抗甲型流感病毒抗体及其用途

Also Published As

Publication number Publication date
CA3225495A1 (en) 2016-01-21
AU2020294340B2 (en) 2024-05-02
CN106604931A (zh) 2017-04-26
ES2869909T3 (es) 2021-10-26
CA2954518A1 (en) 2016-01-21
JP6495434B2 (ja) 2019-04-03
US10077309B2 (en) 2018-09-18
EP3733700A1 (en) 2020-11-04
AU2015289831B2 (en) 2021-01-28
US20170158768A1 (en) 2017-06-08
AU2020294340A1 (en) 2021-02-25
WO2016010978A1 (en) 2016-01-21
EP3172230A1 (en) 2017-05-31
EP3172230A4 (en) 2018-04-18
JP2017527268A (ja) 2017-09-21
CA2954518C (en) 2024-02-20
AU2015289831A1 (en) 2017-02-09
EP3172230B1 (en) 2021-04-14

Similar Documents

Publication Publication Date Title
KR101935088B1 (ko) Ror1 암을 치료하고 전이를 저해하는데 이용을 위한 항체와 백신
CN111356701B (zh) 抗α-突触核蛋白抗体及其用途
JP6553075B2 (ja) さらなるｃｃｒ３−結合ケモカインを認識する抗エオタキシン−２抗体
US11274131B2 (en) IgM-mediated receptor clustering and cell modulation
JP7502865B2 (ja) Ｃ５ａ活性のインヒビターでの炎症性疾患の処置
CN104602708A (zh) 痴呆症治疗药或预防药
JP6366195B2 (ja) 炎症性疾患の予防又は治療剤
CN109476729A (zh) 淀粉样蛋白β的抗体
AU2020294340B2 (en) Compositions and methods for targeting of the surfactant protein a receptor
US12358977B2 (en) Treatment of acute exacerbations of chronic obstructive pulmonary disease by antagonism of the IL-20R
CN117003877A (zh) Prdx1 IgG中和抗体及其制备方法和在制备急性器官损伤或脓毒症药物中的应用
WO2006080756A1 (en) Method and pharmaceutical composition for preventing or treating diseases associated with inflammation
US11655298B2 (en) Composition for treating fulminant acute pneumonia including CD69 antagonist
KR20260052059A (ko) 소변 uC5b-9 검출에 기반한 국소 보체 억제를 통한 보체-매개 질환의 표적 치료
JP6944701B2 (ja) ＣＤ１１ｂアンタゴニストを含む劇症型急性肺炎治療用組成物
CN121773333A (zh) 基于尿uc5b-9检测的通过局部补体抑制对补体介导的疾病进行的靶向治疗
JPWO2007049805A1 (ja) 合成リポペプチドおよびその医薬用途
WO2019226690A1 (en) Treatment of melanoma brain metastasis by inhibition of amyloid precursor protein cleavage

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant